Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1245.50
-24.30 (-1.91%)
< Home < Back

Dr. Reddy’s launches Sevelamer Carbonate Tablets in US

Date: 03-10-2017

Dr. Reddy’s Laboratories has launched Sevelamer Carbonate Tablets, 800 mg, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) Tablets, approved by the US Food and Drug Administration (USFDA). Dr. Reddy’s Sevelamer Carbonate Tablets, 800 mg are available in the bottle count size of 270 tablets.

The Renvela brand and generic had US sales of approximately $1.88 billion MAT for the most recent twelve months ending in July 2017 according to IMS Health. Renvela is a trademark of Genzyme Corporation.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.